<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002153</url>
  </required_header>
  <id_info>
    <org_study_id>247A</org_study_id>
    <secondary_id>DTI-006</secondary_id>
    <nct_id>NCT00002153</nct_id>
  </id_info>
  <brief_title>Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders</brief_title>
  <official_title>Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DEKK-TEC, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma&#xD;
      and lymphoproliferative disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>25</enrollment>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-007</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Maintenance antihormones, hormones, and glucocorticoids.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Histologically proven metastatic cancer including Kaposi's sarcoma and&#xD;
             lymphoproliferative disorders to the skin or cutaneous sites. NOTE:&#xD;
&#xD;
          -  Primary basal or squamous cell cancer of the skin is allowed.&#xD;
&#xD;
          -  Failed both primary and secondary chemotherapy and/or immunotherapy protocols.&#xD;
&#xD;
          -  Measurable skin or cutaneous lesions. 4 Life expectancy of at least 20 weeks.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Prior therapy for cutaneous lesions from Kaposi's sarcoma or lymphoproliferative&#xD;
             disorders.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior maintenance steroids and hormone/antihormone therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active infections other than medically stable HIV infection.&#xD;
&#xD;
          -  Active congestive heart failure, any persistent arrhythmia or transient serious&#xD;
             arrhythmia (ventricular tachycardia, sinoatrial arrest, etc.), or progressive&#xD;
             cardiomyopathy.&#xD;
&#xD;
          -  Unstable blood pressure.&#xD;
&#xD;
          -  Seizures or other CNS disorders.&#xD;
&#xD;
          -  Severe unstable diabetes mellitus.&#xD;
&#xD;
          -  Coagulopathies.&#xD;
&#xD;
          -  Thrombotic disease.&#xD;
&#xD;
          -  Any other medical conditions that would prevent completion of study or produce&#xD;
             significant risk to patient.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Concomitant chemotherapy or immunotherapy.&#xD;
&#xD;
          -  Ongoing corticosteroid therapy (unless maintenance).&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of active cardiopulmonary or respiratory disease.&#xD;
&#xD;
          -  History of sun hypersensitivity and photosensitive dermatoses.&#xD;
&#xD;
          -  History of allergy or hypersensitivity to cosmetics, toiletries, or other&#xD;
             dermatological products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DEKK - TEC Inc</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Skin Neoplasms</keyword>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

